PMH6 - comparative Evaluation of Safety, Efficacy and Cognitive Profile of Amisulpride and Olanzapine in Schizophrenia Patients- A Prospective Study

Abstract

To determine and compare the efficacy, safety, and cognitive profile of Amisulpride and Olanzapine. To determine the types of symptoms experienced by schizophrenic patients. To determine and compare the weight of patients in 2 groups. Prospective comparative study. Six months duration. Safety assessment included adverse event reporting and abnormal involuntary movement scale (AIMS). Primary efficacy variable was the change from baseline in BPRS (Brief Psychiatric Rating Scale) score. Cognitive assessment involved token test, digit vigilance test and animal names test. The total number of patients were also categorised on the basis of symptoms. Out of total 74 patients, 29 patients (39.19%) came with positive symptoms, 37 patients (50%) experience negative symptoms and 8 patients (10.81%) shows mixed symptoms During the study period, change observed in BPRS score in amisulpride group was 16.63±4.617 and in olanzapine group was 14.72 ±2.275 (Table 5). This improvement was similar in both groups and was statistically significant (P <0.0001).Analysis was performed using Graph pad prism software version 6.07. To evaluate cognitive profile, three tests were used, namely, token test, digit vigilance test and animal names test. In all these test amisulpride perform significantly better than olanzapine and hence amisulpride gains an upper hand over olanzapine in improvement of cognitive function. The study showed that amisulpride and olanzapine were equally effective in the treatment of acute exacerbation of schizophrenia as shown by BPRS scores. To conclude, amisulpride and olanzapine show equivalent efficacy in improving psychotic symptoms of schizophrenia. When compared to Olanzapine, Amisulpride gains an upper hand in preserving body weight and in improvement of cognitive functions.